Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JR-141 in Patients With Mucopolysaccharidosis II
NCT03568175Phase 3Completed
- Sponsor
- JCR Pharmaceuticals
- Start
- Aug 2018
- Primary completion
- Feb 2020
- Modality
- Replacement Enzymes, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of pabinafusp alfa in mucopolysaccharidosis type II, sponsored by JCR Pharmaceuticals. Started Aug 2018; status: completed.
02
Drugs
pabinafusp alfa
03
Conditions
mucopolysaccharidosis type II
Beyond the preview
Go deeper on NCT03568175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03568175.